The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, said on 23 February 2021 that Mexico, the first country in North America to approve Russia's Sputnik V COVID-19 vaccine, has received its first batch of the vaccine, CNN reported on Tuesday.
In a statement, the RDIF said: "On 3 February 2021, the Federal Commission for the Protection against Sanitary Risk of Mexico (COFEPRIS) approved Sputnik V under the emergency use authorisation procedure without additional clinical trials in the country."
Kirill Dmitriev, CEO of the RDIF, said: "it is a significant breakthrough in Russia's efforts to fight COVID-19 and clearly shows that saving lives is above politics."
According to figures from the RDIF, which oversees global distribution and sales of the vaccine, Russia's Sputnik V COVID-19 vaccine has now been approved for use in more than 30 countries and is one of the world's most pre-ordered vaccines, with at least 50 countries, from Argentina to the Philippines, ordering nearly 2.5 billion doses so far.
A tally by Johns Hopkins University has revealed that Mexico has the third highest death toll in the world, behind the US and Brazil, with more than 180,000 deaths.
European Commission approves GSK's Arexvy for adults aged 18 and over
PhotonPharma adds Dr. William Warren to board
GSK wins European Commission approval for Shingrix prefilled syringe
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Avetra unveils site-centric CRO operating model
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s